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Abstract
The relationship between the Gly972Arg polymorphism in the insulin receptor substrate-1 (IRS-1) gene and metabolic risk markers is not
clear, possibly due to small sample sizes. Modification by body mass index (BMI) has also been suggested. Our aim was therefore to quantify
the association of this 9 72Arg- variant with insulin, glucose and lipid levels in overweight and non-overweight subjects with oversampling of
subjects with the 972Arg-\anaiA. We first genotyped 3684 subjects selected from a large population-based cohort (n ~ 23,000) according to
BMI (26-40 or 18-24 kg/m2). Next, we examined 600 of these subjects for fasting metabolic risk markers according to BMI-group and geno-
type. Subjects with the 972Arg-variant had significantly higher insulin concentrations (4.09 pmol/1 or 9.6%, P = 0.024) and lower triglyceride
levels (0.13 mmol/1 or 11 %, P = 0.001) compared with non-carriers when adjusted for age, sex, waist-to-hip ratio, BMI, alcohol consumption,
physical activity and cigarette smoking. These associations were more pronounced in the high BMI-group, although the interactions were not
statistically significant Our large population-based sample shows that the IRS-1 Gly972Arg polymorphism relates to higher fasting insulin
levels and lower triglyceride levels. The impact of this genotype and its modification by overweight may be smaller than suggested previously.
© 2003 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
Insulin receptor substrate-1 (IRS-1) occupies a key posi-
tion in the insulin signalling pathway [1]. After binding of
insulin to the a-subunit, the p-subunit of the insulin receptor
undergoes autophosphorylation, and in turn, phosphorylates
other endogenous protein substrates in the cascade of in-
sulin action. As IRS-1 is the first substrate in this cascade,
an impaired IRS-1 function may result in a defect in insulin
signalling.
Several polymorphisms in the IRS-1 gene, located on
chromosome 2q36, have been found [2]. The association be-
tween the so-called Gly972Arg polymorphism and pheno-
types in humans has been studied most extensively, probably
because the prevalence of this genotype is relatively high
(approximately 10%) [3-9]. We recently reported the results
* Corresponding author. Tel.: +31-30-2743479; fax: +31-30-2744407.
E-mail addresses: a.jelleraa@hb.unimass.nl (A. Jellema),
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of a meta-analysis of 27 studies on the association between
this variant and the risk for type 2 diabetes, showing a 25%
increased risk [3]. However, considerable heterogeneity was
observed.
Results of the impact on metabolic risk factors such as
insulin resistance are also not always consistent. Almind [4]
found a higher proportion of carriers among type 2 diabetic
patients compared to controls, but diabetic carriers had lower
fasting insulin concentrations as compared with non-carriers.
Others did not observe differences in fasting insulin con-
centrations or insulin sensitivity between type 2 diabetic
patients with and without the 972Arg-varia.nt [8,9]. On the
other hand, the proportion of carriers was higher in type 2
diabetic patients with either insulin resistance or dyslipi-
daemia [10]. The frequency of the 972Arg-variant was also
significantly higher among Italian patients with coronary
heart disease (CHD) than among controls [6]. In this study,
no associations between insulin or glucose concentrations
with genotype were observed, but independent of CHD, total
cholesterol concentrations were higher in carriers than in
0021-9150/S - see front matter © 2003 Elsevier Ireland Ltd. All rights reserved.
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non-carriers. In contrast, a British study including patients
with diabetes or CHD reported lower total cholesterol
and triglyceride concentrations in carriers compared with
non-carriers [9].
The relationship between the Gly972Arg polymorphism
of the IRS-1 gene and cardiovascular risk parameters may
depend on body weight. This is suggested by the results of
Clausen et al. [7], who observed an association between the
polymorphism and increased fasting glucose, triglyceride,
tissue plasminogen activator concentrations, and decreased
insulin sensitivity in obese but not in non-obese subjects.
Also Baroni et al. [5] observed an association between the
IRS-1 variant and metabolic cardiovascular risk parameters
in obese, but not in non-obese healthy subjects. However, the
number of carriers of the IRS-1 variant in previous studies
was generally small, which probably explains a large part
of the inconsistent findings.
The aim of the present study is therefore to quantify the
interrelationships between the Gly972Arg IRS-1 polymor-
phism and obesity on insulin, glucose and lipid levels in a
large population-based study with oversampling of carriers
of the polymorphism.
2. Subjects and methods
2.1. Subjects
Subjects were selected from participants of the Cardio-
vascular Disease Risk Factor Monitoring Project and the
Monitoring Project on Risk Factors for Chronic Disease
(MORGEN study) in the Maastricht area, in the south of
The Netherlands. A detailed description of these studies
has been published elsewhere [11,12]. The first examina-
tion, which included height and weight measurements and
collecting of non-fasting blood samples, was carried out
between 1987 and 1997. Buffy coats were isolated and
stored at — 20 °C. A re-approach including a questionnaire
on body weight took place in 1998.
For the present study, we selected two groups of Cau-
casian subjects from whom buffy coats were available. The
first group of subjects had a body mass index (BMI) between
19 and 23 kg/m2 at the first physical examination and be-
tween 18 and 24 kg/m2 at the postal re-approach (n = 1732).
The second group had a BMI between 27 and 39 kg/m2
and between 26 and 40 kg/m2 at the examination and postal
re-approach respectively (n — 1952). None of the subjects
had diagnosed diabetes mellitus. Buffy coats of all 3684
subjects, stored for 2-12 years, could be used to determine
the IRS-1 Gly972Arg polymorphism. From this group, all
carriers (n = 519) and a random sample of wildtype sub-
jects (n = 497) were invited for a second physical exami-
nation. Sixty percent of the invitees participated. After the
re-approach, 10 subjects had become diabetic and were ex-
cluded. Thus, data of 600 subjects could be used for the
present analysis. Power analysis showed that this study size
has sufficient power (80% at a P-value of 5%) to detect a
difference in fasting insulin of 10pmol/l (S.D. 30pmol/l)
between carriers and non-carriers among one of the weight
groups, a difference for example observed by Baroni et al.
[5] among lean subjects.
Subjects filled in an informed consent form before the
measurements started. The protocol was approved by the
Medical Ethical Committee of TNO Prevention and Health,
Leiden, The Netherlands.
2.2. Clinical measurements
After an overnight fast, subjects were weighed without
shoes to the nearest 0.1 kg. Waist and hip circumferences
were measured to the nearest 0.1 cm and height was mea-
sured without shoes to the nearest 0.1 cm. Blood was drawn
into a 10ml vacuum tube containing KjEDTA and a 4.5 ml
vacuum tube containing 9M sodium citrate for measure-
ments to be reported elsewhere.
The subjects filled in a general health questionnaire,
which included questions about cigarette smoking, alcohol
consumption and physical activity. Subjects were classified
as cigarette smokers or non-smokers. Alcohol consumption
was categorised as follows: no alcohol, between 0 and 1
glass of alcohol a day, between 1 and 3 glasses of alco-
hol a day, and more than three glasses of alcohol a day.
Bouts of exercise, biking or gardening etc. were included
to assess physical activity if they lasted 30 min per day or
more. Subjects who reported such activities on 3 or more
days a week were considered to be physically active. Sub-
jects active on 0-2 days a week were classified as non-
active.
2.3. Laboratory measurements
DNA was extracted from buffy coats by proteinase K
digestion and phenol extraction [13]. The Gly972Arg poly-
morphism was determined using the conventional poly-
merase chain reaction (PCR), Bsfiil restriction enzyme
analysis and agarose gel electrophoresis as described by Al-
mind [4]. EDTA-plasma was used to measure total choles-
terol and triglyceride, and HDL cholesterol concentrations
after a dextran sulfate-Mg2+ precipitation by enzymatic
methods (Boehringer Mannheim, Germany). If triglyceride
concentrations were below 4.5 mmol/1 LDL cholesterol was
calculated by using the Friedewald equation [14]. Plasma
glucose concentrations were measured with a commercially
available kit (Roche Diagnostica, Basel, Switzerland and
WAKO, Neuss, Germany). Insulin concentrations were de-
termined with a sensitive ELISA kit with cross-reactivity
with C-peptide and proinsulin less than 0.01% (Mercodia,
Uppsala, Sweden). Proinsulin was also measured with an
ELISA kit (Mercodia, Uppsala, Sweden). Insulin resis-
tance was calculated with a homeostasis model assessment
for insulin resistance (HOMAiR) as described previously
[15].
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2.4. Statistical analysis
A Kolmogorov-Smimov test was performed to test nor-
mality of the data. Triglyceride, insulin, proinsulin and
glucose concentrations and HOMAjR were not normally
distributed, but were after a log transformation. Partial
correlation coefficients between variables were calculated
adjusted for age and sex. Differences in subject charac-
teristics between the Gly and Arg-van&rA were examined
by analysis of covariance with adjustments for age and
sex. To examine the interaction between BMI-group (high
or low) with genotype on the metabolic parameters, addi-
tional adjustments were made for waist-to-hip ratio, BMI,
alcohol consumption, physical activity, and cigarette smok-
ing. The interaction term was omitted from the statistical
model if it did not reach statistical significance. In this
way, the effects of the Gly972Arg polymorphism could be
estimated. Data are expressed as mean ± S.D. or median
with inter-quartile range for skewed variables. A two-tailed
value of P < 0.05 was considered to be statistically sig-
nificant. All analyses were performed using SPSS; PC
release 10.0.
3. Results
Among the population-based sample of 3684 subjects
the prevalence of the heterozygous and homozygous forms
of the Gly972Arg polymorphism were 14.1 and 0.5%. The
allele frequencies were not different between the over-
weight and non-overweight group (0.075 versus 0.076).
The distribution of the genotypes was in Hardy-Weinberg
equilibrium (P = 0.75), both in the low and in the high
BMI-group. Participants of the re-examination for metabolic
risk markers (273 men, 327 women) were between 26 and
71 years old. Mean BMI was 21.9 kg/m2 (S.D. 1.4 kg/m2)
in the low BMI-group and 31.2 kg/m2 (S.D. 3.0 kg/m2) in
the high BMI-group. Due to the deliberate oversampling
of the carriers, this final study population included 362
non-carriers, 228 heterozygous carriers and 10 homozygous
carriers of the Gly972Arg polymorphism.
The overweight group was older and included more men
compared with the low BMI-group (Table 1). Comparisons
were therefore made after adjustment for age and sex. Af-
ter this adjustment, carriers in the high BMI-group had a
significantly lower BMI compared with non-carriers. In the
low BMI-group, however, there was no difference in BMI
between carriers and non-carriers. A similar difference be-
tween carriers and non-carriers according to BMI was ob-
served for waist-to-hip ratio (P < 0.001). For all other
parameters, no significant interaction between the IRS-1
Gly972Arg polymorphism and BMI was observed (P >
0.15).
After adjustments for age, sex, BMI, waist-to-hip ratio,
physical activity, alcohol consumption, and cigarette smok-
ing, insulin concentrations were higher in carriers of the
Arg-variant compared with the non-carriers (Table 2). The
difference between carriers and non-carriers in the high
BMI-group, however, was more pronounced than that in
the low BMI-group (6.90pmol/l or 12% versus 2.21 pmol/1
or 7%; Table 3). Insulin resistance as estimated with the
HOMAjR model was also significantly different between
carriers and non-carriers (P = 0.029, Table 2). Glucose and
proinsulin concentrations did not differ between carriers and
non-carriers of the Gly972Arg polymorphism. Triglyceride
concentrations were significantly lower in the Arg-variant
compared with the G/y-variant (0.13 mmol/1 or 11%, P =
0.001, Table 4). Again, differences were more pronounced
in the high BMI-group (Table 5). Total cholesterol, LDL
cholesterol and HDL cholesterol levels were not significantly
different between both groups.
Correlation coefficients of insulin and HOMArR with
other metabolic parameters are listed in Table 6. Correlations
did not differ between the high and low BMI-group. Triglyc-
eride levels were inversely associated with HDL cholesterol
(r = -0.40, P < 0.001).
Table 1
Subject characteristics according to BMI-group and Gly972Arg polymorphism
High BMI-group"
Men (%)
Age (years)
Smoking (% yes)
Alcohol (% yes)
Physical activity (%, >2
days a week)
BMI (kg/m2)
Waist-to-hip ratio
Wildtype
(n = 180)
59.4C
56.4 ± 7.06
17.2
72.8
60.3
31.6 ± 3.04
0.96 ± 0.08
Arg-variant
(n = 124)
52.4
54.6 ± 9.94
16.1
74.2
56.3
30.5 ± 2.78
0.91 ± 0.09
Adjusted
/•-value1"
0.145
0.062
0.831
0.711
0.984
<0.001
<0.001
Low BMI-group
Wildtype
(n = 182)
38.5
49.3 ± 10.3
41.8
70.9
65.9
21.9 ± 1.37
0.81 dfc 0.07
Arg-variant
(n=114)
27.2
49.7 ± 10.6
38.6
71.9
72.7
21.8 ± 1.48
0.80 ± 0.07
Adjusted
/"-value
0.040
0.645
0.528
0.748
0.370
0.742
0.223
a
 Subjects in the high BMI-group had a BMI between 26 and 40 kg/m2, subjects in the low BMI-group had a BMI between 18 and 24 kg/m2 (see
Section 2).
b
 P-values are adjusted for age and sex.
c
 Values are means ± S.O. or percentages.
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Table 2
Crude median values and adjusteda differences in insulin, proinsulin, glucose and HOMAjR according to Gly972Arg polymorphism in the total study
population
Metabolic risk factors Wildtype (n = 362) Arg-variant (n = 238) Adjusted /"-value
Insulin (pmol/1)
Adjusted difference
Proinsulin (pmol/1)
Adjusted difference
Glucose (mmol/1)
Adjusted difference
HOMAIR
Adjusted difference
42.5 (27.8-60.8)b
4.08 (0.55, 7.59)c
6.49 (4.09-12.0)
-0.14 (-0.83, 0.58)
5.17 (4.84-5.63)
-0.02 (-0.11, 0.08)
1.57 (1.05-2.46)
0.16 (0.017, 0.31)
44.8 (31.7-65.3)
5.80 (3.95-10.8)
5.15 (4.77-5.60)
1.70 (1.22-2.61)
0.024
0.718
0.748
0.029
a
 Differences and /"-values are adjusted for age, sex, BMI, waist-to-hip ratio, smoking, physical activity and alcohol consumption by analysis of
covariance.
b
 Values are means with S.D. or medians with inter-quartile ranges for skewed variables.
c
 Values are adjusted differences with 95% confidence intervals.
Table 3
Crude median values and adjusted8 differences in insulin, proinsulin, glucose and according to Gly972Arg polymorphism HOMAiR among the high and
low BMI-group
Metabolic risk factors
Insulin (pmol/1)
Adjusted difference
Proinsulin (pmol/1)
Adjusted difference
Glucose (mmol/1)
Adjusted difference
HOMAIR
Adjusted difference
High BMI-groupb
Wildtype (« = 180)
57.5 (41.0-74.1)c
6.90 (0.17, 13.6)d
10.9 (6.4-17.4)
0.63 (-1.13, 2.39)
5.40 (5.14-5.92)
-0.02 (-0.21, 0.19)
2.34 (1.65-3.19)
0.31 (0.01, 0.61)
Arg-variant Adjusted
(n = 124) lvalue
60.4 (42.3-79.7)
0.044
9.09 (5.57-15.9)
0.483
5.41 (5.04-5.77)
0.835
2.33 (1.66-3.43)
0.042
Low BMI-group
2 Wildtype (n = 182)
30.8 (21.9-44.1)
2.21 (-1.78, 6.21)
4.52 (3.29-6.75)
-0.30 (-0.93, 0.33)
4.93 (4.66-5.20)
-0.02 (-0.12, 0.09)
1.19 (0.87-1.60)
0.07 (-0.07, 0.21)
Arg-variant
(n=114)
35.4 (22.2-46.2)
4.30 (3.09-6.06)
4.85 (4.63-5.24)
1.32 (0.82-1.70)
Adjusted
/"-value
0.279
0.345
0.686
0.327
a
 Differences and /"-values are adjusted for age, sex, BMI, waist-to-hip ratio, smoking, physical activity and alcohol consumption by analysis of
covariance.
b
 Subjects in the high BMI-group had a BMI between 26 and 40 kg/m2, subjects in the low BMI-group had a BMI between 18 and 24 kg/m2 (see
Section 2).
c
 Values are means with S.D. or medians with inter-quartile ranges for skewed variables.
d
 Values are adjusted differences with 95% confidence intervals.
Table 4
Crude means and adjusted8 differences in serum lipids according to Gly972Arg polymorphism in the total study population
Metabolic risk factors Wildtype (n = 362) Arg-variant (n = 238) Adjusted /"-value
Total cholesterol (mmol/1)
Adjusted difference
LDL cholesterol (mmol/1)
Adjusted difference
HDL cholesterol (mmol/1)
Adjusted difference
Triglyceride (mmol/1)
Adjusted difference
5.36 ± 1.02b
0.04 (-0.13, 0.20)c
3.48 ± 0.98
0.13 (-0.03, 0.29)
1.27 ± 0.36
-0.05 (-0.09, 0.003)
1.15 (0.75-1.71)
-0.13 (-0.21, -0.05)
5.35 ± 1.00
3.56 ± 0.93
1.26 ± 0.37
0.98 (0.63-1.52)
0.660
0.119
0.066
0.001
a
 Differences and /"-values are adjusted for age, sex, BMI, waist-to-hip ratio, smoking, physical activity and alcohol consumption by analysis of
covariance.
b
 Values are means with S.D. or medians with inter-quartile ranges for skewed variables.
c
 Values are adjusted differences with 95% confidence intervals.
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Table 5
Crude values and adjusted8 differences in serum lipids according to Gly972Arg polymorphism among the high and low BMI-group
Metabolic risk factors
Total cholesterol (mmol/1)
Adjusted difference
LDL cholesterol (mmol/1)
Adjusted difference
HDL cholesterol (mmol/1)
Adjusted difference
Triglyceride (mmol/1)
Adjusted difference
High BMI-groupb
Wildtype (n = 180)
5.52 ± 0.98°
0.01 (-0.24, 0.26)d
3.65 ± 0.94
0.09 (-0.15, 0.34)
1.11 ± 0.25
-0.01 (-0.07, 0.05)
1.54 (1.04-2.15)
-0.26 (-0.46, -0.06)
Arg-variant
(n = 124)
5.49 ± 0.96
3.74 ± 0.89
1.12 ± 0.28
1.20 (0.82-1.74)
Adjusted
/"-value
0.941
0.443
0.713
0.010
Low BMI-group
Wildtype (n = 182)
5.21 ± 1.04
-0.04 (-0.26, 0.19)
3.31 ± 0.99
0.04 (-0.18, 0.26)
1.44 ± 0.38
-0.06 (-0.14,0.03)
0.91 (0.65-1.25)
-0.12 (-0.22, -0.01)
Arg-variant
(n=114)
5.20 ± 1.02
3.37 ± 0.94
1.41 ± 0.40
0.74 (0.50-1.16)
Adjusted
P-value
0.754
0.730
0.175
0.026
8
 Differences and /"-values are adjusted for age, sex, BMI, waist-to-hip ratio, smoking,
covariance.
b
 Subjects in the high BMI-group had a BMI between 26 and 40 kg/m2, subjects in the
Section 2).
c
 Values are means with S.D. or medians with inter-quartile ranges for skewed variables.
d
 Values are adjusted differences with 95% confidence intervals.
physical activity and alcohol consumption by analysis of
low BMI-group had a BMI between 18 and 24 kg/m2 (see
Table 6
Partial8 correlation coefficients between fasting insulin and HOMAiR and
other metabolic parameters in the total study population
Fasting insulin
Glucose
Proinsulin
Triglycerides
Total cholesterol
LDL cholesterol
HDL cholesterol
Partial r
0.36
0.66
0.31
0.02
0.08
-0.34
P-value
<0.001
<0.001
<0.001
0.548
0.042
<0.001
HOMAiR
Partial r
0.52
0.71
0.34
0.03
0.09
-0.35
P-value
<0.001
<0.001
<0.001
0.468
0.034
<0.001
Results are adjusted for age and sex.
4. Discussion
Previous studies on the impact of the codon P72,4rg-variant
of the IRS-1 gene on metabolic risk factors included a
limited number of carriers, which may partly explain in-
consistencies in the results. Using oversampling of the car-
riers within a population-based cohort we showed that the
*4rg-variant is associated with higher insulin concentrations
and insulin resistance as assessed with the HOMA-model
and lower triglyceride concentrations.
An effect of the Gly972Arg polymorphism of the IRS-1
gene on metabolic risk markers seems plausible, because of
the central role of IRS-1 in the insulin signalling cascade. In
support, Almind et al. [16] found that insulin signalling of
myeloid progenitor cells transfected with the 972Arg-variant
of the human IRS-1 was impaired as compared to cells trans-
fected with wildtype human IRS-1. We recently showed,
based on a meta-analysis of 3408 cases and 5419 controls
from 27 studies, that the 972Arg-\ariant is associated with
a small but significant increased risk of type 2 diabetes [3].
Human studies on metabolic factors, however, are less con-
clusive [4,5,7,9,17] which may be due to the limited num-
ber of carriers included. Further, previous studies have sug-
gested that effects of this polymorphism may depend on
BMI [5,7] with obese carriers, e.g. having up to 81.7 pmol/1
higher fasting insulin levels than obese non-carriers [5].
Using oversampling of the carriers within a population-
based cohort we showed that differences in fasting in-
sulin and HOMAiR between carriers and non-carriers were
more pronounced and statistically significant in the high
BMI-group, but not in the low BMI-group. However, the
differences were smaller than previously suggested. In ad-
dition, despite our large number of carriers the interaction
term testing for modification by overweight was not statis-
tically significant (P = 0.17), indicating that the combined
impact is not very strong.
Our results suggest that the IRS-1 Gly972Arg polymor-
phism is associated with insulin resistance, albeit to modest
extent, whereas lower triglyceride levels were seen. Insulin
resistance is generally associated with increased triglyceride
concentrations [18], and our finding of lower triglyceride
concentrations in carriers of the Arg-variant is therefore
somewhat surprising and may be a chance finding. A sim-
ilar finding has been reported before from type 2 diabetic
patients and subjects with CHD [9], This suggests that the
observation in our population may not be due to chance
only, and that exclusion of diabetic subjects from our study
may not solely explain our results. We can only speculate
about a further explanation. The insulin signalling pathway
is involved in the insulin-dependent inhibition of hepatic
VLDL-triglyceride production [19], but may in the liver in-
volve IRS-2 rather than IRS-1 [2,20]. Therefore, in IRS-1
972Arg carriers, high insulin levels combined with relative
hepatic insulin sensitivity could have resulted in reduced
fasting triglycerides. This, however, remains to be confirmed
by other studies.
Apart from affecting insulin sensitivity, also beta-cell
function may be impaired in the IRS-1 Gly972Arg
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polymorphism. Recently, human pancreatic islets from
972Arg carriers were found to have reduced insulin content,
altered insulin release, and a greater number of immature
secretory granules [21]. However, results of clinical stud-
ies so far are mixed [22,23]. We measured proinsulin as
an indicator of a defect in insulin secretion [24]. Although
proinsulin levels were strongly associated with insulin lev-
els and HOMAiR in our population, they were not different
between carriers and non-carriers of the Arg-variant.
Although fasting insulin and HOMAiR were inversely
associated with HDL cholesterol in our population and
reduced HDL cholesterol levels are a feature of insulin resis-
tance [18], we observed no clear difference in HDL choles-
terol between carriers and non-carriers. Insulin resistance
is in general not uniformly associated with total cholesterol
levels [25]. Indeed, HOMAiR and fasting insulin were not
associated with total cholesterol levels in our population. In
addition, total cholesterol concentrations were not different
between carriers and non-carriers of the 972Arg-variant.
This is in agreement with several other studies [5,7], al-
though also higher [6] or lower [9] cholesterol levels have
been reported in studies with smaller number of carriers.
LDL particle size may change as a consequence of insulin
resistance [26], but has not yet been studied in relation to
the 972Arg-variant, nor has apolipoprotein B.
BMI was 1.2 kg/m2 lower in our carriers than in non-
carriers within the overweight group, and also their waist-
to-hip ratio was reduced. These differences were not
observed in the low BMI-group. A lower BMI and
waist-to-hip ratio were also seen in healthy normal glucose
tolerant 972Arg carriers from Germany [27]. Others ob-
served a positive association between the IRS-1 972 A variant
and body weight [28]. Similarly, in type 2 diabetic patients
an increased BMI in carriers was seen [17]. However, their
control subjects over 40 years of age with the 972Arg-variant
had in contrast a lower BMI compared with non-carriers.
The lower BMI in our overweight carriers might have been
the result from the exclusion of diabetic subjects, as over-
weight carriers are more prone to develop type 2 diabetes.
On the other hand, IRS-1 protein expression is markedly
increased during maturation of human pre-adipocytes and
IRS-1 is also relevant in IGF-1 signalling [2]. Our find-
ings suggest therefore that studies on the impact of the
972Arg-variant on these processes are useful as well.
Finally, the prevalence of the Gly972Arg polymorphism
among the population-based sample of our cohort was
14.6%. It should be noted that regional variance in The
Netherlands has been reported (11-18%), but this was based
on small sample sizes only and may be a chance finding
[29]. Our proportion of carriers fell well within the range of
the two previous observations and agrees with results of two
other population-based studies in The Netherlands (15.3
and 14.1%) (R.M. van Dam, personal communication).
This large population-based study of healthy individuals
shows that presence of the IRS-1 Gly972Arg polymorphism
is associated with increased insulin concentrations and in-
sulin resistance and decreased triglyceride concentrations.
These associations are more pronounced among overweight
subjects, but the combined effect may be smaller than sug-
gested previously.
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